Multiple myeloma tumor progression in the 5T2MM murine model is a multistage and dynamic process of differentiation, proliferation, invasion, and apoptosis

Blood

Volumn 101, Issue 8, 2003, Pages 3136-3141

  Asosingh, Kewal ^a   De Raeve, Hendrik ^b   Van Riet, Ivan ^b   Van Camp, Benjamin ^b   Vanderkerken, Karin ^b  

^a VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CD45 ANTIGEN; INTERLEUKIN 6 RECEPTOR; SYNDECAN 1; DEXAMETHASONE; MEMBRANE PROTEIN; PARAPROTEIN; PROTEOGLYCAN; SDC1 PROTEIN, MOUSE; SYNDECAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BONE MARROW; CANCER CELL; CANCER GROWTH; CANCER REGRESSION; CANCER STAGING; CELL INVASION; CELL ISOLATION; CELL PROLIFERATION; CONTROLLED STUDY; EXPERIMENTAL MODEL; FLOW CYTOMETRY; MICROSCOPY; MOUSE; MULTIPLE MYELOMA; NONHUMAN; PRIORITY JOURNAL; TUMOR DIFFERENTIATION; ANIMAL; BLOOD; BONE MARROW CELL; BONE MARROW TRANSPLANTATION; C57BL MOUSE; CANCER INVASION; CELL CULTURE; CELL DIFFERENTIATION; CELL DIVISION; COCULTURE; CYTOLOGY; DISEASE COURSE; DRUG EFFECT; IMMUNOPHENOTYPING; PATHOLOGY;

ANIMALS; ANTIGENS, CD45; APOPTOSIS; BONE MARROW CELLS; BONE MARROW TRANSPLANTATION; CELL DIFFERENTIATION; CELL DIVISION; COCULTURE TECHNIQUES; DEXAMETHASONE; DISEASE PROGRESSION; FLOW CYTOMETRY; IMMUNOPHENOTYPING; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED C57BL; MULTIPLE MYELOMA; MYELOMA PROTEINS; NEOPLASM INVASIVENESS; PROTEOGLYCANS; RECEPTORS, INTERLEUKIN-6; SYNDECAN-1; SYNDECANS; TUMOR CELLS, CULTURED;

EID: 0037606041     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-10-3000     Document Type: Article

References (41)

1. Vanderkerken K, De Greef C, Asosingh K, et al. Selective initial in vivo homing pattern of 5T2 multiple myeloma cells in the C57BL/KalwRij mouse. Br J Cancer. 2000;82:953-959.
2. Kuehl WM, Bergsagel PL. Multiple myeloma: evolving genetic events and host interactions. Nat Rev Cancer. 2002;2:175-187.
3. Jensen GS, Poppema S, Mant MJ, Pilarski LM. Transition in CD45 isoform expression during differentiation of normal and abnormal B cells. Int Immunol. 1989;1:229-236.
4. Hata H, Xiao H, Petrucci MT, Woodliff J, Chang R. Epstein J. Interleukin-6 gene expression in multiple myeloma: a characteristic of immature tumor cells. Blood. 1993;81:3357-3364.
5. Ishikawa H, Tsuyama N, Abroun S, et al. Requirements of src family kinase activity associated with CD45 for myeloma cell proliferation by interleukin-6. Blood. 2002;99:2172-2178.
6. Joshua D, Petersen A, Brown R, Pope B, Snowdon L, Gibson J. The labelling index of primitive plasma cells determines the clinical behaviour of patients with myelomatosis. Br J Haematol. 1996;94:76-81.
7. Bataille R. A cellular model for myeloma cell growth and proliferation [abstract]. Hematol J. 2002;3(suppl 1):48.
8. Dhodapkar MV, Sanderson RD. Syndecan-1 (CD 138) in myeloma and lymphoid malignancies: a multifunctional regulator of cell behavior within the tumor microenvironment. Leuk Lymphoma. 1999;34:35-43.
9. Hirano T. Interleukin 6 (IL-6) and its receptor: their role in plasma cell neoplasias. Int J Cell Cloning. 1991;9:166-184.
10. Hirano T. Interleukin 6 and its receptor: ten years later. Int Rev Immunol. 1998:16:249-284.
11. Tani Y, Nishimoto N, Ogata A, et al. Gp130 in human myeloma/plasmacytoma. Curr Top Microbiol Immunol. 1995;194:229-233.
12. Kawano M, Hirano T, Matsuda T, et al. Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature. 1988;332:83-85.
13. Klein B, Zhang XG, Jourdan M, et al. Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6. Blood. 1989;73:517-526.
14. Kawano MM, Mihara K, Huang N, Tsujimoto T, Kuramoto A. Differentiation of early plasma cells on bone marrow stromal cells requires interleukin-6 for escaping from apoptosis. Blood. 1995;85:487-494.
15. Radl J, De Glopper ED, Schuit HR, Zurcher C. Idiopathic paraproteinemia, II: transplantation of the paraprotein-producing clone from old to young C57BL/KaLwRij mice. J Immunol. 1979;122:609-613.
16. Radl J, Croese JW, Zurcher C, Van den Enden-Vieveen MH, de Leeuw AM. Animal model of human disease. Multiple myeloma. Am J Pathol. 1988;132:593-597.
17. Vanderkerken K, Asosingh K, Braet F, Van Riet I, Van Camp B. Insulin-like growth factor-1 acts as a chemoattractant factor for 5T2 multiple myeloma cells. Blood. 1999;93:235-241.
18. Vanderkerken K, De Raeve H, Goes E, et al. Organ involvement and phenotypic adhesion profile of 5T2 and 5T33 myeloma cells in the C57BL/KaLwRij mouse. Br J Cancer. 1997:76:451-460.
19. Asosingh K, Renmans W, Van der Gucht K, et al. Circulating CD34+ cells in cord blood and mobilized blood have a different profile of adhesion molecules than bone marrow CD34+ cells. Eur J Haematol. 1998;60:153-160.
20. Asosingh K, Menu E, Van Valckenborgh E, et al. Mechanisms involved in the differential bone marrow homing of CD45 subsets in 5T murine model of myeloma. Clin Exp Metastasis. 2002;19:583-591.
21. Avet-Loiseau H, Facon T, Grosbois B. Oncogenesis of multiple myeloma: 14q32 and 13q chromosomal abnormalities are not randomly distributed, but correlate with natural history, immunological features, and clinical presentation. Blood. 2002;99:2185-2191.
22. Radl J. Age-related monoclonal gammapathies: clinical lessons from the aging C57BL mouse. Immunol Today. 1990:11:234-236.
23. Asosingh K, Radl J, Van Riet I, Van Camp B, Vanderkerken K. The 5TMM series: a useful in vivo mouse model of human multiple myeloma. Hematol J. 2000;1:351-356.
24. Asosingh K, De Raeve H, Croucher P, et al. In vivo homing and differentiation characteristics of mature (CD45-) and immature (CD45+) 5T multiple myeloma cells. Exp Hematol. 2001:29:77-84.
25. Mahmoud MS, Ishikawa H, Fujii R, Kawano MM. Induction of CD45 expression and proliferation in U-266 myeloma cell line by interleukin-6. Blood. 1998;92:3887-3897.
26. Fujii R, Ishikawa H, Mahmoud MS, Asaoku H, Kawano MM. MPC-1-CD49e-immature myeloma cells include CD45+ subpopulations that can proliferate in response to IL-6 in human myelomas. Br J Haematol. 1999;105:131-140.
27. Hilbert DM, Kopf M, Mock BA, Kohler G, Rudikoff S. Interleukin 6 is essential for in vivo development of B lineage neoplasms. J Exp Med. 1995;182:243-248.
28. Grigorieva I, Thomas X, Epstein J. The bone marrow stromal environment is a major factor in myeloma cell resistance to dexamethasone. Exp Hematol. 1998;26:597-603.
29. Cheung WC, Van Ness B. The bone marrow stromal microenvironment influences myeloma therapeutic response in vitro. Leukemia. 2001;15:264-271.
30. Liotta LA, Kohn EC. The microenvironment of the tumour-host interface. Nature. 2001;411:375-379.
31. Zucker S, Cao J, Chen WT. Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment. Oncogene. 2000;19:6642-6650.
32. McCawley LJ, Matrisian LM. Tumor progression: defining the soil round the tumor seed. Curr Biol. 2001;11:R25-R27.
33. Dhodapkar MV, Abe E, Theus A, et al. Syndecan-1 is a multifunctional regulator of myeloma pathobiology: control of tumor cell survival, growth, and bone cell differentiation. Blood. 1998:91:2679-2688.
34. Holen I, Drury NL, Hargreaves PG, Croucher PI. Evidence of a role for a non-matrix-type, metalloproteinase activity in the shedding of syndecan-1 from human myeloma cells. Br J Haematol. 2001;114:414-421.
35. Bayer-Garner IB, Sanderson RD, Dhodapkar MV, Owens RB, Wilson CS. Syndecan-1 (CD138) immunoreactivity in bone marrow biopsies of multiple myeloma: shed syndecan-1 accumulates in fibrotic regions. Mod Pathol, 2001;14:1052-1058.
36. Yang Y, Yaccoby S, Liu W, et al. Soluble syndecan-1 promotes growth of myeloma tumors in vivo. Blood. 2002;100:610-617.
37. Rawstron AC, Barrans SL, Blythe D, et al. In multiple myeloma, only a single stage of neoplastic plasma cell differentiation can be identified by VLA-5 and CD45 expression. Br J Haematol. 2001;113:794-802.
38. Yaccoby S, Epstein J. The proliferative potential of myeloma plasma cells manifest in the SCID-hu host. Blood. 1999:94:3576-3582.
39. Irie-Sasaki J, Sasaki T, Matsumoto W, et al. CD45 is a JAK phosphatase and negatively regulates cytokine receptor signalling. Nature. 2001;409:349-354.
40. Arimura Y, Ogimoto M, Mitomo K, et al. CD45 is required for CD40-induced inhibition of DNA synthesis and regulation of c-Jun NH2-terminal kinase and p38 in BAL-17 B cells. J Biol Chem. 2001;276:8550-8556.
41. Hallek M, Bergsagel PL, Anderson KC. Multiple myeloma: increasing evidence for a multistep transformation process. Blood. 1998;91:3-21.